Oligometastatic Carcinoma — Trials

Oligometastatic Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

19 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 16
Recruiting: 7
Ph III recruiting: 1
Growth YoY: —
Industry share: 6%
Top sponsor: Mayo Clinic
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06058663	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma	recruiting	Phase 1	16	Mayo ClinicOTHER	1	May 13, 2026	clinicaltrials
NCT06229366	[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer(ACCEL)	active not recruiting	Phase 1	142	Eli Lilly and CompanyINDUSTRY	1	Dec 22, 2025